Loading…
Aristo Bio-Tech and Lifescience (ARISTO)₹108.00+3.85%Pesticides & Agrochemicals
In the Mar 2026 quarter (standalone), Aristo Bio-Tech and Lifescience reported sales of ₹107 Cr, up 2.8% from Mar 2025, and net profit of ₹2.99 Cr. For the year to Mar 2026, sales were ₹363 Cr and net profit ₹6.98 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 88.83 | 133 | 112 | 214 | 104 | 255 | 107 |
| Expenses | 84.75 | 128 | 109 | 205 | 103 | 248 | 98.69 |
| Operating Profit | 4.01 | 5.01 | 3.01 | 8.01 | 1.01 | 8.01 | 8.01 |
| OPM % | 4.1% | 4.0% | 2.9% | 3.8% | 1.1% | 3.1% | 7.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 1.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 2.99 |
| Depreciation | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Profit before tax | 0.99 | 3.99 | 1.99 | 5.99 | −0.99 | 5.99 | 3.99 |
| Tax % | 12.9% | 28.0% | 27.0% | 25.0% | −18.1% | 25.0% | 27.0% |
| Net Profit | 0.99 | 2.99 | 0.99 | 4.99 | 0.00 | 3.99 | 2.99 |
| EPS (Rs) | 1.48 | 3.79 | 1.93 | 6.69 | −0.73 | 6.14 | 4.43 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56.89 | 159 | 270 | 201 | 200 | 166 | 166 | 218 | 244 | 317 | 363 |
| Expenses | 55.80 | 157 | 262 | 194 | 196 | 162 | 159 | 208 | 235 | 308 | 347 |
| Operating Profit | 1.01 | 3.01 | 7.01 | 7.01 | 5.01 | 4.01 | 5.01 | 9.01 | 8.01 | 9.01 | 16.01 |
| OPM % | 1.6% | 1.6% | 2.7% | 3.4% | 2.2% | 2.6% | 3.3% | 4.0% | 3.5% | 2.9% | 4.4% |
| Other Income | 0.00 | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.99 | 1.99 | 1.99 | 2.99 | 1.99 | 1.99 | 2.99 | 1.99 | 1.99 | 3.99 |
| Depreciation | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 3.01 | 3.01 |
| Profit before tax | 0.99 | 2.99 | 5.98 | 3.99 | 0.99 | 1.99 | 1.99 | 4.99 | 4.99 | 4.99 | 9.98 |
| Tax % | 32.9% | 30.9% | 34.0% | 30.9% | 28.0% | 28.0% | 27.9% | 24.9% | 28.0% | 25.9% | 26.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.00 | 1.99 | 3.99 | 2.99 | 0.99 | 0.99 | 0.99 | 3.99 | 3.99 | 3.98 | 6.98 |
| EPS (Rs) | 4.01 | 18.53 | 37.45 | 5.68 | 2.03 | 2.17 | 2.15 | 5.24 | 5.72 | 5.97 | 10.56 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 5.0% | 7.0% | 8.0% | 6.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 0.99 | 4.99 | 4.99 | 4.99 | 4.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| Reserves | 2.01 | 4.02 | 7.02 | 6.02 | 7.03 | 8.03 | 10.04 | 23.08 | 27.09 | 31.11 | 38.12 |
| Borrowings | 5.02 | 10.03 | 20.08 | 14.06 | 20.07 | 22.09 | 25.10 | 22.09 | 21.06 | 22.08 | 35.10 |
| Other Liabilities | 19.98 | 71.93 | 59.87 | 64.95 | 55.88 | 45.90 | 36.87 | 46.77 | 72.89 | 80.84 | 74.72 |
| Total Liabilities | 27.00 | 86.97 | 88.96 | 91.02 | 87.97 | 81.01 | 77.00 | 99.93 | 127 | 141 | 155 |
| Fixed Assets | 1.99 | 2.01 | 8.01 | 8.01 | 7.99 | 11.99 | 13.99 | 15.99 | 21.99 | 23.99 | 23.99 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.99 | 2.99 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 25.01 | 84.96 | 80.95 | 81.02 | 76.99 | 69.02 | 63.01 | 82.95 | 106 | 117 | 131 |
| Inventories | 9.04 | 27.10 | 29.10 | 33.13 | 24.08 | 32.12 | 24.10 | 31.11 | 40.13 | 47.16 | 63.20 |
| Trade receivables | 14.05 | 53.18 | 48.10 | 42.14 | 48.16 | 33.08 | 33.10 | 45.13 | 57.20 | 56.12 | 55.16 |
| Cash & equivalents | 0.00 | 0.99 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 1.99 | 0.99 | 0.99 | 2.99 |
| Total Assets | 27.00 | 86.97 | 88.96 | 91.02 | 87.97 | 81.01 | 77.00 | 99.93 | 127 | 141 | 155 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −4.01 | 1.01 | 8.02 | 1.01 | 2.01 | 7.02 | −3.01 | 8.02 | 10.03 | 8.02 |
| Cash from investing activity | 0.00 | −5.01 | −2.01 | −2.01 | −2.01 | −3.01 | −4.01 | −7.01 | −5.01 | −3.01 |
| Cash from financing activity | 3.98 | 3.99 | −5.98 | 0.99 | −0.99 | −2.99 | 7.97 | −1.99 | −3.99 | −3.99 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | −0.99 | 0.00 | 1.99 |
| Capex | 0.34 | 0.98 | 0.61 | 0.88 | 1.45 | 3.26 | 2.81 | 6.57 | 5.12 | 2.97 |
| Free cash flow | −4.01 | 0.00 | 6.01 | −1.01 | 0.00 | 4.01 | −7.01 | 1.01 | 5.01 | 5.01 |
| CFO / OP % | −123.0% | 38.0% | 138.0% | 40.0% | 60.0% | 134.0% | −17.0% | 106.0% | 123.0% | 69.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 91 | 120 | 64 | 76 | 87 | 71 | 72 | 74 | 85 | 64 | 54 |
| Inventory days | 66 | 67 | 42 | 65 | 47 | 78 | 60 | 57 | 65 | 59 | 70 |
| Days payable | 142 | 177 | 85 | 124 | 74 | 93 | 87 | 85 | 112 | 97 | 78 |
| Cash conversion cycle | 16 | 11 | 23 | 18 | 61 | 56 | 46 | 48 | 38 | 26 | 46 |
| Working capital days | 3 | 14 | 14 | 15 | 20 | 28 | 25 | 37 | 31 | 22 | 25 |
| ROCE % | — | 31.0% | 33.9% | 23.9% | 14.0% | 11.0% | 11.9% | 16.0% | 12.9% | 12.0% | 20.0% |
For the Mar 2026 quarter, Aristo Bio-Tech and Lifescience reported sales of ₹107 Cr, up 2.8% year on year and net profit of ₹2.99 Cr. The operating margin was 7.9%.
Aristo Bio-Tech and Lifescience's sales for the year to Mar 2026 were ₹363 Cr.
Net profit for the year to Mar 2026 was ₹6.98 Cr. Earnings per share over the same trailing period were ₹10.56.
Aristo Bio-Tech and Lifescience reported borrowings of ₹35.10 Cr at Mar 2026, against cash and equivalents of ₹2.99 Cr.
Cash from operations was ₹8.02 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹5.01 Cr.